FY23 AGM Notes
Opening remarks by Mr. Sadu - Link
Answers for the questions posed by share holders Link
Growth Triggers
- China is 1 Billion dollar opportunity for Gland in injectables space
- Biologics - Biosimilar CDMO Infrastructure in place (learned hard way by failing in vaccine venture)
- Not going to work on Biosimilar development, focus is in partnership with innovators / partners
- Focusing more on process efficiencies, that is already translated into the best volume growth in the industry (Achieved 21% volume growth in FY22 )
- Every year the new product launches are contributing 8-10%
- 4 Complex injectables are in the pipe line to be launched this FY that has $1B opportunity
Capex
- 300 crores in FY23, 250 crores in FY24 (Spent on expanding capacities like microsphere combiline )
Risk Mitigation
- Actively working on alternate API suppliers
- Alternate packaging suppliers for fill and finish products
News
